Pulmonx to Report Fourth Quarter and Full Year 2020 Financial Results on March 2, 2021

Rhea-AI Summary

Pulmonx Corporation (NASDAQ: LUNG) will release its financial results for Q4 and full year 2020 on March 2, 2021, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. The company focuses on minimally invasive treatments for severe emphysema, with its Zephyr® Endobronchial Valve approved by the FDA as a breakthrough device. The valve has been utilized in over 20,000 patients worldwide. For more details, visit their investor webpage.

Positive

• FDA pre-market approval for Zephyr Valve as a breakthrough device.
• Over 80,000 Zephyr Valves used to treat over 20,000 patients.

Negative

• None.

REDWOOD CITY, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2020 after the close of trading on Tuesday, March 2, 2021. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Investors interested in listening to the conference call may do so by dialing (833) 614-1518 for domestic callers or (270) 823-1072 for international callers, followed by Conference ID: 6144267. A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx Corporation
Pulmonx Corporation (NASDAQ: LUNG) is a commercial-stage medical technology company that provides minimally invasive treatment for patients with severe emphysema, a form of COPD. The Pulmonx solution, which is comprised of the Zephyr® Endobronchial Valve, the Chartis® Pulmonary Assessment System and the StratX® Lung Analysis Platform, is designed to treat severe emphysema/COPD patients who, despite medical management, are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, with over 80,000 valves used to treat more than 20,000 patients. For more information on the Zephyr Valves, please visit www.MyLungsMyLife.com. For more information on the company, please visit www.Pulmonx.com.

Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com 

FAQ

When will Pulmonx release its financial results for 2020?

Pulmonx will release its financial results on March 2, 2021.

What is the conference call schedule for Pulmonx's financial results?

The conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET on March 2, 2021.

What is the significance of the Zephyr Valve for Pulmonx?

The Zephyr Valve is a FDA-approved breakthrough device for treating severe emphysema, crucial for Pulmonx's offerings.

How many Zephyr Valves have been utilized globally?

More than 80,000 Zephyr Valves have been used to treat over 20,000 patients worldwide.